Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • acquistions

    - PMLiVE

    Lilly and MeiraGTx partner in $475m ophthalmology deal

    The companies will develop and commercialise therapies for genetic conditions

    - PMLiVE

    Merck to expand ophthalmology pipeline with acquisition of EyeBio in deal worth up to $3bn

    Merck will gain access to EyeBio’s Restoret to prevent and treat retinal vascular leakage-associated vision loss

    - PMLiVE

    Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

    The company will gain the rights to use 4DMT’s gene therapy vector for at least one target

    - PMLiVE

    Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

    The transaction includes the Swiss drugmaker’s anti-inflammatory eye drop Xiidra

    - PMLiVE

    Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

    Bayer's Eylea remains the drug to beat, however

    - PMLiVE

    Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

    A rapid round-up of the top pharma, biotech and healthcare news

    - PMLiVE

    FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

    Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

    - PMLiVE

    Takeda agrees $5.2bn deal to buy Ariad

    Acquires cancer firm in the first big pharma M&A deal of 2017

    - PMLiVE

    Valeant uncouples Dendreon and skincare brands to cut debt

    Agrees deals worth $2.1bn with L’Oreal and Sanpower Group

    - PMLiVE

    Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’

    Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands

    - PMLiVE

    Torrid times at Gilead lead to calls for a major M&A deal

    HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

    - PMLiVE

    Valeant’s ex-CEO and CFO ‘could face criminal charges’

    Sources suggest probe may relate to the company’s former relationship with Philidor Rx Services

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links